613 related articles for article (PubMed ID: 18310816)
41. Biomarkers of bone health and osteoporosis risk.
Eastell R; Hannon RA
Proc Nutr Soc; 2008 May; 67(2):157-62. PubMed ID: 18412989
[TBL] [Abstract][Full Text] [Related]
42. Bone health medications: research questions versus clinical choices.
Goldstein SR
Menopause; 2011 Aug; 18(8):835-6. PubMed ID: 21785375
[No Abstract] [Full Text] [Related]
43. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib.
Komatsubara S; Mori S; Mashiba T; Li J; Nonaka K; Kaji Y; Akiyama T; Miyamoto K; Cao Y; Kawanishi J; Norimatsu H
J Bone Miner Res; 2004 Jun; 19(6):999-1005. PubMed ID: 15125797
[TBL] [Abstract][Full Text] [Related]
44. A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage.
Nyman JS; Yeh OC; Hazelwood SJ; Martin RB
Bone; 2004 Jul; 35(1):296-305. PubMed ID: 15207770
[TBL] [Abstract][Full Text] [Related]
45. Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment?
Devogelaer JP; Boutsen Y; Gruson D; Manicourt D
Rheum Dis Clin North Am; 2011 Aug; 37(3):365-86, v-vi. PubMed ID: 22023897
[TBL] [Abstract][Full Text] [Related]
46. Prevention of postmenopausal bone loss and treatment of osteoporosis.
Kleerekoper M
Semin Reprod Med; 2005 May; 23(2):141-8. PubMed ID: 15852199
[TBL] [Abstract][Full Text] [Related]
47. Bone microdamage and skeletal fragility in osteoporotic and stress fractures.
Burr DB; Forwood MR; Fyhrie DP; Martin RB; Schaffler MB; Turner CH
J Bone Miner Res; 1997 Jan; 12(1):6-15. PubMed ID: 9240720
[TBL] [Abstract][Full Text] [Related]
48. Bisphosphonates: how do they work?
Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
Suzuki A; Sekiguchi S; Asano S; Itoh M
J Pharmacol Sci; 2008 Apr; 106(4):530-5. PubMed ID: 18431035
[TBL] [Abstract][Full Text] [Related]
50. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
[TBL] [Abstract][Full Text] [Related]
51. [Determinants of bone quality and strength independent of bone remodeling].
Saito M; Marumo K
Clin Calcium; 2016 Jan; 26(1):29-41. PubMed ID: 26728528
[TBL] [Abstract][Full Text] [Related]
52. [Adherence to medications for treatment of osteoporosis].
Tanaka I; Oshima H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():329-34. PubMed ID: 18161126
[No Abstract] [Full Text] [Related]
53. [Is SSBT associated with atypical femoral fracture? SSBT is associated with atypical femoral fracture - pathophysiology of atypical femoral fractures - ].
Mashiba T
Clin Calcium; 2012 Jun; 22(6):914-8. PubMed ID: 22653033
[TBL] [Abstract][Full Text] [Related]
54. [SSBT (severely suppressed bone turnover) ].
Mori S
Clin Calcium; 2013 Mar; 23(3):365-70. PubMed ID: 23445889
[TBL] [Abstract][Full Text] [Related]
55. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
56. [Treatment and prevention of osteoporosis in patients with decreased renal function].
Vestergaard P; Eiken PA
Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452
[TBL] [Abstract][Full Text] [Related]
57. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.
Reginster JY; Collette J; Neuprez A; Zegels B; Deroisy R; Bruyere O
Bone; 2008 May; 42(5):832-6. PubMed ID: 18316258
[TBL] [Abstract][Full Text] [Related]
58. [Quality of bones].
Qiu MC; Zhu M
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):723-4. PubMed ID: 15949372
[No Abstract] [Full Text] [Related]
59. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
[TBL] [Abstract][Full Text] [Related]
60. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Kobayashi H; Hamaya E
Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):37-48. PubMed ID: 15738620
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
